Computer Assisted Ambulatory EEG Monitoring for Early Onset Alzheimer's Disease
Trial Summary
Do I need to stop taking my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more information.
What data supports the idea that Computer Assisted Ambulatory EEG Monitoring for Early Onset Alzheimer's Disease is an effective treatment?
The available research shows that Computer Assisted Ambulatory EEG Monitoring can provide valuable information about the progression of Alzheimer's disease. For example, one study found that patients with abnormal EEG patterns at the early stage of the disease experienced a more severe decline in cognitive functions compared to those with normal EEG patterns. Another study indicated that EEG markers could help identify Alzheimer's patients who might need more clinical attention due to their 'frailty'. While these studies highlight the usefulness of EEG in predicting disease progression and patient outcomes, they do not directly show that EEG monitoring is an effective treatment for Alzheimer's disease itself. Instead, they suggest that EEG can be a helpful tool in managing and understanding the condition.12345
What safety data exists for Computer Assisted Ambulatory EEG Monitoring?
The provided research does not directly address safety data for Computer Assisted Ambulatory EEG Monitoring. However, it highlights that ambulatory EEG (AEEG) is a well-established technique used for long-term monitoring in various settings, including at home, and is considered a cost-effective alternative to inpatient monitoring. The studies emphasize the importance of technical standards to ensure quality, but specific safety data is not mentioned.678910
Is the treatment in the trial 'Computer Assisted Ambulatory EEG Monitoring for Early Onset Alzheimer's Disease' a promising treatment?
Yes, the treatment is promising because EEG monitoring can help predict the progression of Alzheimer's disease, identify patients who may need more attention, and differentiate between Alzheimer's patients and healthy individuals. This can lead to better management and care for those with the disease.12111213
What is the purpose of this trial?
Researchers are trying to determine the frequency of seizures and epilepsy in patients with Early-onset Alzheimer's disease (EOAD) using a 48-hour computer assisted ambulatory electroencephalogram.
Research Team
Neill Graff-Radford, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for people aged 40-64 with Early-onset Alzheimer's Disease (EOAD) who have a partner to report on their daily activities. Participants must not be pregnant, should speak English, and show amyloid presence in PET scans. They need to meet criteria for mild cognitive impairment or probable AD dementia with a global CDR score of ≤ 1.0.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
EEG Monitoring
Participants undergo a 48-hour computer assisted ambulatory electroencephalogram to determine the frequency of seizures and epilepsy
Follow-up
Participants are monitored for safety and effectiveness after EEG monitoring
Treatment Details
Interventions
- Computer assisted ambulatory electroencephalogram
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor